'''CureVac N.V.''' is a German [[biopharmaceutical]] company that creates [[Nucleoside-modified messenger RNA|therapies]] based on [[messenger RNA]] (mRNA). It is headquartered in [[Tübingen]], [[Germany]]. The company was founded in 2000 by [[Ingmar Hoerr]] (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), [[Günther Jung]], and [[Hans-Georg Rammensee]].  
 
 CureVac had about 240 employees in November 2015. < ref name= " fiercebiotech.com " > {{cite web|title=Gates, Hopp back $110M megaround for CureVac's mRNA work|url=https://www.fiercebiotech.com/venture-capital/gates-hopp-back-110m-megaround-for-curevac-s-mrna-work}} < /ref >   
 
 The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. < ref > {{cite web|last1=Carroll|first1=John|title=Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines|url=https://endpts.com/eli-lilly-is-making-a-1-8b-leap-into-the-mrna-field-targeting-next-gen-cancer-vaccines/|website=endpts.com|date=18 October 2017}} < /ref > 
 
 ==References== 
 {{reflist}} 
 
 {{stub}} 
 [[Category:Healthcare companies of Germany]] 
 [[Category:Baden-Württemberg]]